An Ayurvedic herb is causing a lot of excitement for it’s brain-boosting powers. Here’s what the evidence shows.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

As I've grown older and experienced the vagaries of my ageing memory, I've often reflected on the possibility of a miracle cure that would rejuvenate ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Looking for the name of Marcel Proust on search engines, it seems that the centenary of his death (1922) has gone unnoticed by medical doctors. Several essays on his illness have already been ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.